Sanofi (EPA:SAN)
86.61
+0.66 (0.77%)
Nov 11, 2026, 5:39 PM CET
Sanofi Revenue
Sanofi had revenue of 15.23B EUR in the quarter ending September 30, 2026, with 15.66% growth. This brings the company's total for the last twelve months to 50.98B, up 11.00% year-over-year. In the year 2025, Sanofi had annual revenue of 46.72B with 5.49% growth. That makes Sanofi the 225th largest company in the world by revenue and 12th in France.
Revenue (ttm)
50.98B
Revenue Growth
+11.00%
P/S Ratio
2.04
Revenue / Employee
681.16K
Employees
74,846
Market Cap
103.76B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Sanofi breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 46.72B | 2.43B | 5.49% |
| Dec 31, 2024 | 44.29B | 2.67B | 6.41% |
| Dec 31, 2023 | 41.62B | 1.06B | 2.61% |
| Dec 31, 2022 | 40.56B | 1.39B | 3.54% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | 37.63B | 1.95B | 5.48% |
| Dec 31, 2018 | 35.68B | -544.00M | -1.50% |
| Dec 31, 2017 | 36.22B | 1.53B | 4.40% |
| Dec 31, 2016 | 34.70B | -165.00M | -0.47% |
| Dec 31, 2015 | 34.86B | 2.86B | 8.94% |
| Dec 31, 2014 | 32.00B | 708.00M | 2.26% |
| Dec 31, 2013 | 31.29B | -4.67B | -12.98% |
| Dec 31, 2012 | 35.96B | 899.00M | 2.56% |
| Dec 31, 2011 | 35.06B | 1.02B | 3.00% |
| Dec 31, 2010 | 34.04B | 2.80B | 8.98% |
| Dec 31, 2009 | 31.23B | 2.42B | 8.38% |
| Dec 31, 2008 | 28.82B | -390.00M | -1.34% |
| Dec 31, 2007 | 29.21B | -282.00M | -0.96% |
| Dec 31, 2006 | 29.49B | 976.00M | 3.42% |
| Dec 31, 2005 | 28.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 29.29B |
| Eurofins Scientific SE | 7.39B |
| emeis Société anonyme | 6.00B |
| Clariane SE | 5.35B |
| Ipsen | 4.29B |
| bioMérieux | 3.99B |
| Sartorius Stedim Biotech | 3.06B |
| Virbac | 1.49B |
Sanofi News
- 1 day ago - FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications - The Guardian
- 2 days ago - Sanofi upgraded to Outperform from Neutral at BNP Paribas - TheFly
- 5 days ago - Novavax Q3 Earnings Call Highlights - Nasdaq
- 6 days ago - Novavax (NVAX) Q3 2026 Earnings Call Transcript - The Motley Fool
- 7 days ago - Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development - Investor's Business Daily
- 8 days ago - Sanofi price target raised to EUR 86 from EUR 82 at Morgan Stanley - TheFly
- 9 days ago - Sanofi price target raised to EUR 90 from EUR 83 at Barclays - TheFly
- 9 days ago - Sanofi price target raised to EUR 80 from EUR 75 at RBC Capital - TheFly